Bellerophon Therapeutics, Inc. (BLPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
BLPH Stock Price Chart Interactive Chart >
BLPH Price/Volume Stats
|Current price||$1.05||52-week high||$5.95|
|Prev. close||$0.94||52-week low||$0.67|
|Day high||$1.07||Avg. volume||55,133|
|50-day MA||$1.66||Dividend yield||N/A|
|200-day MA||$2.79||Market Cap||10.02M|
Bellerophon Therapeutics, Inc. (BLPH) Company Bio
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is founded in Warren, New Jersey.
Most Popular Stories View All
BLPH Latest News Stream
|Loading, please wait...|
BLPH Latest Social Stream
View Full BLPH Social Stream
Latest BLPH News From Around the Web
Below are the latest news stories about Bellerophon Therapeutics Inc that investors may wish to consider to help them evaluate BLPH as an investment opportunity.
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022. The Company’s presentation will be available on-demand
Last Friday, Bellerophon (BLPH) announced positive top-line data from a recently concluded Phase 2 dose escalation study (PULSE-PHPF-002), looking at the acute hemodynamic benefit of Bellerophon’s INOpulse system as a therapy for pulmonary hypertension associated with sarcoidosis (PH-Sarc). The Phase 2 testing was set up as a proof of concept study to see if the system could show hemodynamic benefit in PH-Sarc. The results were promising, as across the three doses used in the study, all 8 subjects displayed a reduction in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). The treatment appears safe too, with no adverse events noted.
The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!
Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis
Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial Treatment was safe and well-tolerated, with no treatment-emergent adverse events observed during the acute hemodynamic dose escalation phase of the study WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments fo
Northern Trust Corp lessened its position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 51.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 36,555 shares of the biotechnology companys stock after selling 39,024 shares during the quarter. Northern Trust Corps holdings in Bellerophon Therapeutics were worth $177,000 at the end of the most 
BLPH Price Returns